Table 4.
Only AML patients develop NuSAP1 Ab and CHAF1b antibody after HCT
| Yes | No | P | |
|---|---|---|---|
| NuSAP1 antibody | n = 24 | n = 96 | |
| Median patient age, y | 46 | 50 | .88 |
| Median donor age, y | 40 | 50 | .44 |
| Conditioning | .36 | ||
| Myeloablative | 13 | 40 | |
| Nonmyeloablative | 11 | 56 | |
| Donor | .16 | ||
| Related | 16 | 78 | |
| Unrelated | 8 | 18 | |
| IgG levels | 907 mg/dL | 643 mg/dL | < .001 |
| Acute GVHD | 1.00 | ||
| 0-I | 20 | 81 | |
| II-IV (15%) | 4 | 15 | |
| Chronic GVHD | .64 | ||
| Yes (66%) | 17 | 62 | |
| No | 7 | 34 | |
| Relapse | .007 | ||
| Yes (28%) | 1 | 29 | |
| No | 23 | 67 | |
| Disease | < .001 | ||
| AML | 24 | 13 | |
| Other diseases | 0 | 83 | |
| CHAF1b antibody | n = 10 | n = 110 | |
| Median patient age, y | 40 | 50 | .44 |
| Median donor age, y | 48 | 48 | .70 |
| Conditioning | .75 | ||
| Myeloablative | 5 | 48 | |
| Nonmyeloablative | 5 | 62 | |
| Donor | .052 | ||
| Related | 5 | 87 | |
| Unrelated | 5 | 23 | |
| IgG levels | 850 mg/dL | 682 mg/dL | < .001 |
| Acute GVHD | 1.00 | ||
| 0-I | 9 | 93 | |
| II-IV (15%) | 1 | 17 | |
| Chronic GVHD | .49 | ||
| Yes (66%) | 8 | 71 | |
| No | 2 | 39 | |
| Relapse | 1.00 | ||
| Yes (28%) | 2 | 29 | |
| No | 8 | 81 | |
| Disease | .001 | ||
| AML | 8 | 29 | |
| Other diseases | 2 | 81 |
One hundred twenty patients were screened for antibodies against NuSAP1 and CHAF1b. The patients were segregated into 2 groups. The first group shows patients with antibody and the second group was detected with no antibody responses. These 2 groups are correlated with variables as shown.